Ruvalcaba syndrome

Ruvalcaba syndrome (also known as Ruvalcaba-Myhre syndrome or Ruvalcaba-Myhre-Smith syndrome) is an extremely rare genetic condition characterized by short stature, skeletal anomalies, and intellectual disability. The syndrome was first described by Ruvalcaba and colleagues and primarily affects the skeletal system, the central nervous system, and craniofacial development. Key clinical features include short stature with delayed bone age, characteristic facial features (narrow maxilla, downslanting palpebral fissures, thin upper lip, and small mouth), brachydactyly (short fingers), small hands and feet, microcephaly, and mild to moderate intellectual disability. Some patients may also exhibit hypogenitalism and pectus carinatum (protruding chest). It is important to distinguish Ruvalcaba syndrome (Orphanet code 3121) from the overlapping but distinct Bannayan-Riley-Ruvalcaba syndrome (BRRS), which involves PTEN gene mutations and features macrocephaly, lipomas, and hamartomatous polyps. Ruvalcaba syndrome as described here does not share the same molecular basis as BRRS. There is currently no specific or curative treatment for Ruvalcaba syndrome. Management is supportive and symptomatic, focusing on developmental support, educational interventions for intellectual disability, and orthopedic monitoring for skeletal anomalies. Growth hormone therapy may be considered in cases of significant short stature, though evidence for its efficacy in this specific condition is limited. Regular follow-up with a multidisciplinary team including genetics, pediatrics, and orthopedics is recommended.

Common questions about Ruvalcaba syndrome